ALT Stock Short Report Raises Concerns over Altimmune's Weight-Loss Drug

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Altimmune Inc. faces disappointment with its weight-loss drug, leading to a 19% stock drop. What does this mean for retail investors? Find out here.

problem of being overweight, a person's legs in close-up.
Biotech Company Altimmune Plunges After Short Report on Weight-Loss Drug

What You Need To Know

Altimmune Inc. (NASDAQ: ALT), a biotechnology company, saw its share price drop after it came to light that Kerrisdale Capital Management has a short position in ALT stock.

The report claims that Altimmune's drug has little chance of competing with established incumbents or other GLP-1 agonists in clinical trials. GLP-1 agonists are drugs that mimic the action of the GLP-1 hormone, which is involved in blood sugar regulation and appetite control.

Shares of Altimmune dropped 19% following the report although they appear to have recovered and ALT stock is up 3% in early trading. Altimmune had previously attempted to develop an intranasal Covid-19 vaccine but discontinued the trial in June 2021.

Despite Kerrisdale's bearish stance, Wall Street analysts are more bullish on Altimmune, with seven analysts rating the stock as a buy.

Altimmune shares are down over 16% YTD.

Why This Is Important for Retail Investors

  1. Investment Impact: The disappointing prospects for Altimmune's weight-loss drug could significantly impact the company's stock price, making it crucial for retail investors to stay informed about the developments. The initial 19% drop in share value following the short report highlights the potential volatility and financial implications for investors.

  2. Market Potential: The weight-loss drug market is highly lucrative, with successful drugs propelling companies like Eli Lilly's LLY stock and NOVO stock to great heights. Understanding Altimmune's standing in this competitive market can help retail investors assess the company's growth potential and make informed investment decisions.

  3. Clinical Trials: The short report raises concerns about Altimmune's ability to compete against both established incumbents and other drugs progressing through clinical trials. Retail investors should consider the implications of the report on Altimmune's clinical trial outcomes and the subsequent impact on the company's valuation.

  4. Track Record: Altimmune's previous attempt at developing a Covid-19 vaccine, which was ultimately discontinued, indicates the company's track record in drug development. Retail investors should assess this history and evaluate the potential risks associated with Altimmune's current obesity program.

  5. Analyst Recommendations: The disparity between Kerrisdale's bearish stance and Wall Street's more bullish outlook presents an opportunity for retail investors to analyze differing opinions. Understanding the views of various analysts and their target price projections can help investors evaluate the overall investment sentiment surrounding Altimmune.

How Can You Use This Information?

Here are some of the investing ideas that can be explored using this information:

Growth Investing

Growth investing focuses on stocks of companies expected to grow at an above-average rate compared to other stocks in the market. Learn more in our article titled 'What is Growth Investing?'.

Retail investors can assess Altimmune's growth potential in the weight-loss drug market, considering the potential impact on its stock price and future prospects.

Event-Driven Strategy

An event-driven strategy capitalizes on stock mispricing that may occur before or after a corporate event, such as a merger or acquisition.

The short report and subsequent stock drop present an opportunity for event-driven investors to take advantage of potential price movements and volatility in Altimmune's stock.

Speculative Investing

Speculative investing engages in high-risk investments with the potential for substantial rewards, often over a short time frame.

Given the uncertainty surrounding Altimmune's weight-loss drug, speculative investors may be interested in evaluating the risks and potential rewards associated with investing in the company's stock.

Contrarian Investing

Contrarian investing involves taking positions against prevailing market trends on the belief that the crowd is wrong.

With the divergence between Kerrisdale's bearish view and Wall Street's more positive outlook, contrarian investors might consider taking a closer look at Altimmune ALT stock and evaluating whether the negative sentiment presents a potential buying opportunity.

Sector Rotation

Sector Rotation is the practice of shifting investment capital from one industry sector to another to take advantage of the economic cycle.

Investors practicing sector rotation strategies may evaluate the prospects of the weight-loss drug market. They can consider reallocating investments to sectors with more favorable growth potential than Altimmune's industry, given the concerns about the drug's competitiveness.

Read What Others Are Saying

Bloomberg: Obesity-Drug Developer Altimmune Sinks on Short-Seller Report

Reuters: Altimmune shares slide after Kerrisdale Capital takes short position

What you should read next:

Popular ETFs

Some investors prefer to invest in stocks via an exchange-traded fund for ease and reduced risk. Some popular ETFs include the following:

  • Large-Caps: Vanguard Mega Cap ETF (MGC)

  • Mid-Caps: Vanguard Mid-Cap ETF (VO)

  • Small-Caps: Vanguard Small-Cap ETF (VB)

  • Growth: iShares Core S&P U.S. Growth ETF (IUSG)

  • Value: iShares Core S&P US Value ETF (IUSV)

  • Emerging Markets: Vanguard FTSE Emerging Markets ETF (VWO)

  • Developed Markets: Vanguard FTSE Developed Markets ETF (VEA)

  • Agg Bonds: iShares Core U.S. Aggregate Bond ETF (AGG) - This ETF provides broad exposure to U.S. investment-grade bonds.

  • TIPS: iShares TIPS Bond ETF (TIP) - This ETF offers exposure to U.S. Treasury Inflation-Protected Securities (TIPS). TIPS are government bonds specifically designed to help protect against inflation.

  • REITs: Vanguard Real Estate ETF (VNQ)

  • Commodities: iShares S&P GSCI Commodity Indexed Trust (GSG)

  • Energy: Energy Select Sector SPDR Fund (XLE)

  • Clean Energy: Invesco Winderhill Clean Energy ETF (PBW)

  • Obesity and Heart Disease: Tema Cardiovascular and Metabolic ETF (HRTS)

Explore more on these topics:



This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter